ABBV · Earnings call · 2026Q3T · Full report

Aesthetic Care Demand Trends

AbbVie Inc. · 2026-10-30 · Importance 43 · Surprise 32

Aesthetics sales were nearly $1.2 billion, down 1.8% operationally; Botox Cosmetic grew 4.1%, while Juvéderm declined 11.8% amid continued weakness in key dermal-filler markets. Management said economic uncertainty and lower consumer confidence had pressured the category for several quarters but that signs of stability were emerging, alongside improving global market growth. The commercial rollout of the fast-acting, short-duration toxin Boey was underway in Europe and Canada, where patient satisfaction was high, particularly regarding rapid onset.